Objective: Based on the PubMed database, this study summarized and analyzed the efficacy of intravenous immunoglobulin in the treatment of Kawasaki disease, so as to provide a reference for the clinical treatment of Kawasaki disease and reduce the risk of cardiovascular events and death in children with Kawasaki disease. Methods: The PubMed database was searched for randomized controlled trials (RCTS) related to IVIG and Kawasaki disease. Then, appropriate literature was selected for initial screening based on the abstracts. The content of the literature was further studied, and the literature on the same topic as this study was selected for inclusion and analysis. This paper used the Cochrane risk bias assessment tool to evaluate the quality of the literatures with highly relevant content. After determining the quality of the literature, RevMan5.4.1 software was used to conduct a meta-analysis of the important indicators in the literature. Results: A total of 120 articles on intravenous immunoglobulin in the treatment of Kawasaki disease were obtained. After further screening, excluding the literature with incomplete data, selective reporting and obvious bias, 13 literatures were finally selected for quality assessment. All 13 articles passed the quality assessment and were subsequently subjected to Meta-analysis. A total of 2337 patients were collected from 13 studies, including 1291 cases in the experimental group and 1046 cases in the control group. There was no significant difference in the initial clinical symptoms between the two groups. After treatment, CRP was significantly decreased [95%CI (-7.53, -4.61), P<0.00001]and sodium concentration was significantly increased [95%CI (-4.02, -0.76), P=0.004], indicating that the symptoms of the child were significantly improved and the physical function was recovered. In addition, it was found that the crying of the children decreased after treatment, so IVIG could relieve the anxiety of the children. Conclusion: The summary results of 13 literatures confirmed that IVIG treatment of children with Kawasaki disease can effectively reduce the clinical symptoms of children and relieve the anxiety of children.